

CUMULATIVE INDEX 1996

Volume 17

March	THE LUNG IN LIVER DISEASE, pages 1-173
June	THE SEPSIS SYNDROME, pages 175-353
September	RECENT ADVANCES IN MECHANICAL VENTILATION, pages 355-619
December	PULMONARY COMPLICATIONS OF HIV INFECTION, pages 621-822

Note: Page numbers of article titles are in **boldface** type.

ABGs. See *Arterial blood gas(es)*.
Abscess(es), lung, in illicit drug users, 801
N-Acetylcysteine, for ARDS, 227
for sepsis, 297-299
Acquired immunodeficiency syndrome (AIDS). See also *Human immunodeficiency virus (HIV) infection*.
acute respiratory failure in, noninvasive ventilation for, 530-531
defined, 621
interstitial lung disease and, 634
macrophage alveolitis and, mechanisms in, 638
Pneumocystis carinii pneumonia and, 621
prevalence, 621
pulmonary complications, demographic factors in, 624-625
ACTG 116B/117, for HIV infection, 651-652
ACTG 155, for HIV infection, 652-653
ACTG 175, for HIV infection, 650-652, 653
ACTG 229, for HIV infection, 653
Acute lung injury, current concepts of, 213-235
ventilatory management of, pressure-targeted approach to, 571-572
Acute respiratory distress, mechanical ventilation and, 441-442
Acute respiratory distress syndrome (ARDS),
barotrauma versus volutrauma in, 560
mechanical ventilation in, modes of, 570-571
noninvasive ventilation for, 528-529
PEEP in, 560-563
permissive hypercapnia in, 565
tidal compliance in, 563
tidal recruitment in, 563
ventilator-induced, 556-560
ventilatory management of, 555-575
adjuncts to, 565-570
extrapulmonary gas exchange, 566
high-frequency ventilation in, 563-566
nitric oxide, 568-570
partial liquid ventilation, 567-568
pressure-targeted approach to, 571-572
prone positioning, 566-567
prostacyclin, 568-570
surfactant administration, 566
tracheal gas insufflation, 568
Acute respiratory failure (ARF), described, 513
hypoxicemic, pediatric, noninvasive ventilation for, 532-533
in asthmatics, noninvasive ventilation for, 522-524
in *Pneumocystis carinii* pneumonia, prognostic markers of, 676-678
noninvasive ventilation for, 513-553. See also *Noninvasive ventilation*.
postextubation, and difficult weaning, 533-535
Adenovirus infection, of lung, in HIV infection, 750
Adhesion molecules, in lipopolysaccharide-induced sepsis syndrome, 190-191
Adnoviral infections, following liver transplantation, 108
Adrenergic drugs, gas exchange effects on, 60
Adult respiratory distress syndrome (ARDS), N-acetylcysteine for, 227
anti-cytokines for, 226-227
anti-endotoxins for, 226-227
as component of multiple-organ dysfunction syndrome, 216
causes, 215
clinical evaluation, 216
corticosteroids for, 226
CT in, 216-217
defined, 213
described, 128
epidemiology, 214-216
fiberoptic bronchoscopy in, 217
following liver transplantation, 104-105
in acute lung injury, 128
in liver cirrhosis, 147-148
in sepsis, 213-235
frequency of, 215-216
ketoconazole for, 227
mechanical ventilation in, 229
nitric oxide for, 228
outcome from, 230
perflubron for, 227-228
permissive hypercapnia in, 229
prevalence, 214-216
prone position ventilation in, 229-230

Adult respiratory distress syndrome (ARDS) (*Continued*)
 pulmonary edema in, treatment, 229
 pulmonary intravascular phagocytosis and, 148–149
 sepsis in, treatment, 228
 surfactant replacement for, 227
 treatment, 226–228
 vasodilators for, 227
 Afterload, defined, 238
 AIDS. See *Acquired immunodeficiency syndrome*.
 Airway(s), difficult, tube placement into, 355
 Airway disease, upper, in HIV-infected children, 792
 Airway management, in critically ill patients, algorithm for, 358
 prolonged, intubation for, 370–371
 tracheotomy for, 371–372
 Airway occlusion pressure, during mechanical ventilation, 460
 Airway pressure(s), in respiration, 577–579
 Airway pressure profile, during mechanical ventilation, measurement of, 465
 Airway resistance, in COPD, 579–580
 Almitrine bismesylate, gas exchange effects on, 59–60
 Alveolar macrophages, in lungs of HIV-infected patients, 638–640
 cytokine release, 639–640
 phenotypic features, 638–639
 Alveolitis, lymphocytic, HIV-related, pathogenesis, 635–636
 in HIV infection, 765–766
 macrophage, AIDS-related, mechanism in, 638
 neutrophilic, in HIV-infected patients, 640
 Aminoglycoside(s), for sepsis, 179
 Amphotericin B, for cryptococcosis, 728–729
 Anastomosis(es), portal vein-to-pulmonary vein, in chronic liver disease, 3–6
 pulmonary artery-to-pulmonary vein, through pleural channels, in chronic liver disease, 2–3
 Anergy testing, in HIV-infected patients, 699
 Angiography, pulmonary, in hepatopulmonary syndrome, 42–44
 Anti-cytokine(s), for ARDS, 226–227
 for sepsis, 310–313
 Anti-endotoxin(s), for ARDS, 226–227
 for sepsis, 309–310
 Antioxidant(s), as inflammatory mediator in sepsis, 205
 for sepsis, 295–297
 Antiretroviral therapy, for HIV infection, 647–662. See also specific drugs and *Human immunodeficiency virus (HIV) infection, antiretroviral therapy for*.
 α₁-Antitrypsin deficiency, 67–74
 described, 67–70, 151–152
 features, 152
 medical therapy for, 71–72
 National Institutes of Health Registry for, 73–74
 natural history, 70–71
 organ transplantation for, expectations from, 72–73
 treatment, 152
 Arachidonic acid metabolites, in hepatopulmonary syndrome, 154
 in lipopolysaccharide-induced sepsis syndrome, 190
 ARDS. See *Acute respiratory distress syndrome; Adult respiratory distress syndrome*.
 L-Arginine–nitrous oxide pathways, biochemical aspects of, 334
 Arterial blood gas(es) (ABGs), measurement of, 453–454
 timing of sampling, 453–454
 Arterial blood gas (ABG) analysis, in pulmonary disease evaluation in HIV-infected patients, 771–772
 Arteriovenous shunting, in liver cirrhosis, 50–51
 Aspergillosis, 739–741
 clinical features, 739–740
 diagnosis, 740
 epidemiology, 739
 microbiology of, 739
 prevention, 741
 treatment, 740–741
 Aspiration, interbronchial, 597
 Aspirin, for sepsis, 290–291
 Asthma, acute respiratory failure in, noninvasive ventilation for, 522–524
 HIV infection in illicit drug users and, 804
 Atelectasis, acute respiratory failure in, noninvasive ventilation for, 532
 following liver transplantation, 104
 HIV infection in illicit drug users and, 804
 Atrial natriuretic factor (ANF), in hepatopulmonary syndrome, 153–154
 Augustine Guide, for orotracheal intubation, 362, 363
 Auto-PEEP. See *Auto-positive end-expiratory pressure (PEEP)*.
 Auto-positive end-expiratory pressure (PEEP), and
 dynamic hyperinflation, 379–394
 with flow limitation, 380–383
 without flow limitation, 383–385
 described, 379
 during mechanical ventilation, measurement of, 464–465
 in clinical management, 388–391
 in COPD, 379–394
 in pressure-controlled ventilation, 401, 403
 in respiration, 577–579
 in volume-cycled ventilation, 396–398
 measurement of, 388–391
 physiologic mechanisms of, 380–388
 rationale for, 380–388
 without dynamic hyperinflation, 385–388
 AZT. See *Zidovudine*.

Bacteremia, defined, 175
 Bacteria, gram-negative, sepsis syndrome due to, 183–184
 Bacterial infections, in HIV-infected children, 791
 in HIV-infected patients, fiberoptic bronchoscopy for, 776–777
 Barbiturate(s), for translaryngeal intubation, 366
 Barotrauma, during mechanical ventilation, 445
 versus volutrauma, in ARDS, 560
 Baseline pressure, minimization of, 412
 Benzodiazepine(s), for translaryngeal intubation, 366
 Bile duct ligation model, in experimental liver disease, 141–143
 Biliary cirrhosis, rats with, hemodynamic studies, 137–138
 Blastomycosis, 736–737
 clinical features, 737
 diagnosis, 737
 epidemiology, 736–737
 microbiology of, 736
 prevention, 737
 treatment, 737
 Blood cultures, in sepsis, 177–178
 Blood gas(es), arterial, in hepatopulmonary syndrome, 40–41
 Blood tests, in pulmonary disease evaluation in HIV-infected patients, 772–773
 BMS 019, for HIV infection, 652
Bordetella sp., infections due to, in HIV-infection, 751
 Bougie, gum elastic, 359, 360

Bradykinin antagonists, for sepsis, 200
 Breath(s), pressure-limited, enhancements in, 415–416
 Breathing, work of, during mechanical ventilation, measurement of, 467
 Breathing pattern, measurement of, during mechanical ventilation, 460–462
 Bristol-Myers Squibb 010, for HIV infection, 652
 Bronchiectasis, in illicit drug users, 801
 Bronchitis, in illicit drug users, 801
 Bronchoalveolar lavage (BAL), in pulmonary complications of HIV infection, 632
 Bronchodilator(s), in respiration, 586–588
 Bronchogenic carcinoma, HIV infection in illicit drug users and, 804
 Bronchopleural fistula, lung separation due to, 598–599
 Bronchopulmonary dysplasia (BPD), 603
 Bronchoscope(s), flexible fiberoptic, translaryngeal intubation with, 358
 Bronchoscopy, fiberoptic, in ARDS evaluation, 217 in pulmonary disease evaluation in HIV-infected patients, 775–778
 Bullous disease, HIV infection in illicit drug users and, 801–802

Calcification, pulmonary, following liver transplantation, 105–106
 Calcitonin gene-related peptide (CGRP), in hepatopulmonary syndrome, 153
 Calcium homeostasis, alterations in, in sepsis-induced metabolic alterations, 255–257
 Cancer, lung, in HIV-infected patients, 759–760
Candida species, hepatic cytokine production in, 89–90
 Candidiasis, 741–743
 clinical features, 741–742
 diagnosis, 742
 epidemiology, 741
 in HIV infection, 726
 prevalence, trends in, 623
 prevention, 742–743
 treatment, 742
 Capillary(ies), alveolar, dilated, in chronic liver disease, 6–8
 Capnography, 457–460
 Carbon dioxide removal, during high-frequency ventilation in newborns, 611
 extracorporeal, in mechanical ventilation, 492–493
 in mechanical ventilation, adjuncts to, 492–498
 in neonatal mechanical ventilation, 608–609
 Carbontetrachloride model, in experimental liver disease, 143–144
 Cardiac dysfunction, during septic shock, 237–248. See also *Septic shock, cardiac dysfunction during*.
 Cardiogenic pulmonary edema, acute respiratory distress in, noninvasive ventilation for, 526–528
 Catheter(s), endotracheal tube exchange over, 359, 361
 gum elastic bougie, 359, 360
 CD4+ cells, in lungs of HIV-infected patients, 634–635
 CD8 cells, in lungs of HIV-infected patients, 635
 Cefuroxime, for sepsis, 179
 Chest radiography, in pulmonary disease evaluation in HIV-infected patients, 768–769
 Children, HIV infection in, 787–796. See also *Human immunodeficiency virus (HIV) infection, in children*.
 hypoxic acute respiratory failure in, noninvasive ventilation for, 532–533
 Chronic obstructive pulmonary disease (COPD), airway resistance in, 579–580
 auto-PEEP in, 379–394, 577–579
 bronchodilators in, 586–588
 controlled hypoventilation with permissive hypercapnia, 585–586
 corticosteroids in, 586–588
 expiratory flow limitation in, 580–581
 mechanical ventilation in, 577–590
 pulmonary hyperinflation, 581–585
 respiratory mechanics, 577–581
 noninvasive ventilation for, 516–522
 outcome following, 588
 PEEP in, 580–581
 Cidofovir, for CMV, 659
 Circuit resistance, in mechanical ventilation, 432
 Cirrhosis, biliary, rats with, hemodynamic studies, 137–138
 hypoxic pulmonary vasoconstriction in, 138–140
 liver, 49–66
 ARDS in, 147–148
 chronic, pulmonary intravascular macrophages in, 132–133
 gas exchange impairment in, at rest, 50–55
 mechanisms of, 49–66
 pathogenesis, 58–59
 pulmonary intravascular macrophages in, induction of, mechanisms for, 145–146
 vascular permeability changes in, 140–141
 primary biliary, 74–75
 Clindamycin-primaquine, for *Pneumocystis carinii* pneumonia, 682–683
 Coaxial techniques, in lung separation, 592
 Coccidioidomycosis, 733–736
 clinical features, 734
 diagnosis, 734–735
 epidemiology, 734
 microbiology of, 733–734
 prevention, 735–736
 treatment, 735
 Colony-stimulating factors, in sepsis, 320
 Complement, as inflammatory mediator in sepsis, 203 in lipopolysaccharide-induced sepsis syndrome, 190
 Compliance, effective dynamic, during mechanical ventilation, measurement of, 463
 static, during mechanical ventilation, measurement of, 462–463
 Computed tomography (CT), in ARDS evaluation, 216–217
 in pulmonary disease evaluation in HIV-infected patients, 768–769
 Computer(s), in weaning from mechanical ventilation, 486
 Continuous positive airway pressure (CPAP), for COPD patients with acute respiratory failure, 516
 mask, clinical application of, 518–520
 COPD. See *Chronic obstructive pulmonary disease*.
 Corticosteroid(s), for ARDS, 226
 for *Pneumocystis carinii* pneumonia, 683–684
 gas exchange effects on, 60
 in respiration, 586–588
 Cricothyroidectomy, 360
 Cryptococcosis, 727–730
 clinical features, 728
 diagnosis, 728
 epidemiology, 727–728
 in HIV-infection, 726
 microbiology of, 727
 prevalence, trends in, 623
 prevention, 730
 treatment, 728–730
 Cryptosporidiosis, bronchopulmonary, in HIV infection, 750–751

Cryptosporidiosis (*Continued*)
 prevalence, trends in, 623
 CT. See *Computed tomography*.
 Cyclooxygenase inhibitors, for sepsis, 289–292
 Cyclophosphamide, gas exchange effects on, 60
 Cystic fibrosis, and lung transplantation, acute
 respiratory failure associated with, noninvasive ventilation for, 525
 Cytokine(s), as inflammatory mediator in sepsis, 203–204
 biology, in liver disease, 89
 induction, in lipopolysaccharide-induced sepsis syndrome, 185–190
 kinetics, during nonbacteremic versus bacteremic hepatic oxidative stress, 90
 macrophage-derived, lung damage due to, 640
 release of, by alveolar macrophages in HIV-infected patients, 639–640
 transcription and secretion of, in sepsis-induced lung injury, 218–219
 Cytomegalovirus (CMV) infection, following liver transplantation, 107–108
 in HIV-infected children, 790
 in HIV-infected patients, blood tests for, 773
 new developments in, 658–660
 prevalence, trends in, 623
 Cytomegalovirus (CMV) pneumonitis, in HIV infection, 746–748

ddC, for HIV infection, 650
 ddl, for HIV infection, 650–651
 Dobutamine, for sepsis, 282–283
 Dopamine, for sepsis, 282
 Drug users, illicit, HIV infection in, 797–807. See also *Human immunodeficiency virus (HIV) infection, in illicit drug users*.
 Dynamic hyperinflation, in mechanical ventilation, 429–430
 ventilatory determinants of, 582–583

Echocardiography, contrast-enhanced, in hepatopulmonary syndrome, 41–42
 Edema, pulmonary, cardiogenic, acute respiratory distress in, noninvasive ventilation for, 526–528
 in liver transplant recipients, 100–101
 Education, for noninvasive ventilation, 545
 Effusion(s), pleural, 76–77
 following liver transplantation, 104
 in liver transplant recipients, 101–102
 Emphysema, HIV infection in illicit drug users and, 801–802
 End-expiratory lung volume, importance of, in ARDS, 560–563
 Endobronchial blockers, in lung separation, 591
 Endocarditis, in illicit drug users, 800–801
 Endothelial activation, nitric oxide and, 341
 Endothelial cells, as inflammatory mediator in sepsis, 207–209
 Endothelium, described, 21
 Endothelin-derived relaxing factor, 154–155
 Endotoxemia, pulmonary intravascular macrophages in, 132–133
 Endotoxin, as inflammatory mediator in sepsis, 201–203
 Endotracheal intubation, equipment for, 362–366
 Endotracheal tube(s), blood from, during mechanical ventilation, 446–447

double-lumen, for endotracheal intubation, 362, 363
 in lung separation, 592–596
 in lung separation, 591–592
 malposition of, complications due to, 369
 Endotracheal tube exchange over a catheter, 359, 361
 Epinephrine, for sepsis, 282
 Epithelial cells, in inflammatory cell activation in sepsis, 208–209
 Epstein-Barr virus (EBV), following liver transplantation, 108
 of lung, in HIV infection, 749
 Erythromycin, for sepsis, 179
 E-selectin, in sepsis-induced lung injury, 220
 Esophageal tubes, placement of, detection of, 365–366
 Esophageal–tracheal Combitube (ETC), for endotracheal intubation, 364–365
 Estrogen, and induction of pulmonary intravascular macrophages in liver cirrhosis, 145–146
 Ethical issues, in intubation, 372–373
 Etomidate, for translaryngeal intubation, 366
 Exercise, gas exchange during, 55–58
 Expiratory flow limitation, assessment, 391
 in COPD, 580–581
 Extrapulmonary gas exchange, in ARDS, 566
 Extrapulmonary infection, *Pneumocystis carinii* pneumonia and, 678–679
 Extubation, criteria for, in weaning from mechanical ventilation, 478
 tracheal, 369–370

Facial skin necrosis, noninvasive ventilation and, 545
 Fc receptors, in lipopolysaccharide-induced sepsis syndrome, 191
 Fentanyl, for translaryngeal intubation, 367
 Fiberoptic bronchoscopy, in ARDS evaluation, 217
 in pulmonary disease evaluation in HIV-infected patients, 775–778
 Fighting the ventilator, mechanical ventilation and, 441–442
 Fistula(s), bronchopleural, lung separation due to, 598–599
 Flow delivery, in mechanical ventilation, 431–432
 Flow limitation, auto-PEEP and dynamic hyperinflation with, 380–383
 auto-PEEP and dynamic hyperinflation without, 383–385
 Flow profile, in volume-cycled ventilation, 399–400
 Flow rate, in volume-cycled ventilation, 398–399
 Flow–volume curves, during mechanical ventilation, measurement of, 465–466
 Flucconazole, for cryptococcosis, 728–730
 Flucytosine, for cryptococcosis, 728–730
 Fluid(s), in sepsis, 279–281
 Flumazenil, for translaryngeal intubation, 366
 Foscarnet, for CMV, 659
 Fungal infections, in HIV-infected children, 791
 in HIV-infected patients, 725–744
 blood tests for, 772–773
 overlap disease, 741–743
 phagocyte opportunists in, 739–741
 T-cell opportunists in, 727–739
 new developments in, 657
 Fungal pneumonia, following liver transplantation, 109
 in illicit drug users, 801
 Fungal sepsis, hepatic cytokine production in, 89–90

Gallium (Ga-67) scanning, in pulmonary disease evaluation in HIV-infected patients, 769–771

Ganciclovir, for CMV, 659, 660

Gas exchange, at rest, 50–55
historical background, 50–51
MIGET, 51–55
during exercise, 55–58
during mechanical ventilation, 453–460
external intervention effects on, 59–62
extrapulmonary, in ARDS, 566
impairment in, in liver cirrhosis, mechanisms of, 49–66. See also under *Cirrhosis, liver, gas exchange impairment in*

perfluorocarbon-associated, for improving oxygenation, in mechanical ventilation, 502–504

Gastric distention, noninvasive ventilation and, 544

Gastrointestinal tract, nitric oxide and, 342

Glucagon, in hepatopulmonary syndrome, 152–153

Glucose, metabolism of, in sepsis, 251–253

Granulocyte colony-stimulating factor, and neutrophil function, 322–323
in infected hosts, 323–327
in sepsis, 320–322

Gum elastic bougie, 359, 360

Haemophilus influenzae, in HIV-type 1 infection, 713, 714–715

Heart, physiology of, 237–238

Hemoptysis, massive, 596

Hepatic cytokine secretory capacity, 88–89

Hepatic hydrothorax, 76–77

Hepatic oxidative stress, nonbacteremic versus bacteremic, cytokine kinetics during, 90

Hepatic veno-occlusive disease, 76

Hepatitis C, chronic, 75–76

Hepatocyte growth factor/scatter factor, 157–162
biologic properties, 160–162
described, 157–158
genomic structure, 158–159
protein-structure-function relationships, 159

Hepatocyte growth factor/scatter factor receptor, 159–160

Hepatopulmonary syndrome, 1, 35–48, 152–155
animal models of, 137–141
clinical manifestations, 39–40
described, 35
diagnostic modalities in, 40–44
hypoxemia in, mechanism of, 36–37
intrapulmonary vascular dilatations in, mechanism of, 37–38
liver diseases associated with, 39
liver transplantation for, 115–123
early history, 115–116
future prospects, 121
recent experience with, 116–118
remaining uncertainties associated with, 121
resolution following, 119–121
pathophysiology, 36
pulmonary hemodynamics, 38–39
resolution of, following liver transplantation, 119–121
reversibility of, predictors of, 118–119
treatment, 44–46

Herpes simplex virus (HSV), following liver transplantation, 108

Herpes simplex virus (HSV) pneumonitis, in HIV infection, 748–749

Herpesvirus infections, in HIV infection, 746–749

High-frequency ventilation (HFV), 417–419
in ARDS, 563–566

High-pressure alarm, repeated, mechanical ventilation and, 442–445

Histoplasmosis, 730–733
clinical features, 731–732
diagnosis, 732
epidemiology, 730–731
in HIV-infected patients, blood tests for, 772–773
microbiology of, 730
prevention, 733
treatment, 733

HIV infection. See *Human immunodeficiency virus (HIV) infection*.

Homeostasis, calcium, alterations in, in sepsis-induced metabolic alterations, 255–257
normal, 255–257

HSV. See *Herpes simplex virus*.

Human immunodeficiency virus (HIV) infection. See also *Acquired immunodeficiency syndrome*.
ACTG 116B/117 for, 651–652
ACTG 155 for, 652–653
ACTG 175 for, 650–652, 653
ACTG 229 for, 653
anergy testing in, 699
antiretroviral therapy for, 647–662
ACTG 116B/117, 652
ACTG 155, 653
ACTG 175, 651, 653
ACTG 229, 654
AZT, 647, 649–650
BMS 019, 653
Bristol-Myers Squibb 010, 652–653
ddC, 650
ddl, 650
NUCA 3001, 652
NUCA 3002, 654
NUCB 3002, 654
AZT for, 649–655
BMS 019 for, 652
Bristol-Myers Squibb 010 for, 652
clinical manifestations, 647–662
ACTG 175, 650–652
CMV and, blood tests for, 773
ddC for, 650
ddl for, 650–651
immune function affected by, 623–624
in children, 787–796
bacterial infections, 791
clinical course of, 788
CMV infection, 790
fungal infections, 791
Kaposi's sarcoma, 792
maternal-fetal transmission, 787–788
Mycobacterium avium-intracellulare infection, 790
noninfectious disorders, 791–792
opportunistic infections, 788–791
Pneumocystis carinii pneumonia, 788–789
tuberculosis, 789–790
upper airway disease, 792
viral infections, 790–791
with respiratory symptoms, 792
in illicit drug users, 797–807
noninfectious complications, 801–804
pathophysiology, 798–799
pulmonary infections due to, 799–801
in its second decade, 792
inhaled, HIV infection in, 804–805
intensive care of patients with, 627–629
lymphocytic alveolitis in, 765–766
lymphocytic interstitial pneumonitis in, 763–766
malignancies with, Kaposi's sarcoma, 755–758
lung cancer, 759–760
non-Hodgkin's lymphoma, 758–759

Human immunodeficiency virus (HIV)
infection (Continued)

- pulmonary complications, 755–761
- mycobacterial complications, 697–711
- diagnosis, 699–700
- mycobacterial diseases with, 701
- new developments in, 655–660
- nonspecific interstitial pneumonitis in, 764–765
- NUCA 3001 for, 651
- NUCA 3002 for, 653
- NUCB 3002 for, 653
- of lung T lymphocytes, 641–642
- of pulmonary macrophages, 641
- pathogenesis of, 647–649
- Pneumocystis carinii pneumonia* and, 621. See *Pneumocystis carinii pneumonia, in HIV-infected patients*.
- pulmonary complications, alveolar macrophages in, 638–640
- approach to patients with, 767–785
- arterial blood gas analysis for, 771–772
- blood tests for, 772–773
- bronchoalveolar lavage for, 633
- chest radiography for, 768–769
- CT for, 768–769
- fiberoptic bronchoscopy for, 775–776
- fungal, 725–744. See also *Fungal infections, in HIV-infection*.
- immunologic-related, 633–645
- lymphocyte compartmentalization, 634–638
- overview, 621–631
- pleural disease, 778–780
- polymorphonuclear cells, 640–641
- pulmonary function tests for, 771
- pulse oximetry for, 772
- radionuclide scans for, 769–771
- respiratory symptoms, 625–626
- sputum examination for, 773–775
- TCR repertoire in, 636–637
- thoracoscopy for, 778
- thoracotomy for, 778
- transthoracic needle aspiration for, 778
- types, 626–627
- pulmonary defenses and, 633–641
- pulmonary function in, 626
- pulmonary immunocompetent cells in, 641–642
- tuberculin skin testing in, 699
- tuberculosis and, 697–702. See also *Tuberculosis, in HIV-infected patients*.
- viral infections in, 745–754. See also *Viral infections, pulmonary, in HIV-infection*.

Human immunodeficiency virus (HIV) infection study, pulmonary complications, 624

Human immunodeficiency virus (HIV) infection-type 1

- bacterial pneumonia associated with, 713–723
- clinical manifestations, 716
- diagnosis, 716–718
- epidemiology, 714–715
- pathophysiology, 713–714
- prevention, 720–721
- treatment, 718–720
- nosocomial pneumonia in, 715–716

Human immunodeficiency virus (HIV) infection-type 1

- RNA quantitation, in clinical practice, 655–656

Hypercapnia, permissive, controlled hypoventilation with, 585–586

- in ARDS, 229, 565

Hypercapnic respiratory failure, noninvasive ventilation for, 516

Hyperinflation, complications of, 583–584

- assessing risk of, 584–585

dynamic, auto-PEEP and, 379–394

- auto-PEEP without, 385–388
- in mechanical ventilation, 429–430
- ventilatory determinants of, 582–583

pulmonary, in COPD, 581–585

Hypertension, portal noncirrhotic, 76

- pulmonary.** See *Pulmonary hypertension*.

Hypotension, mechanical ventilation and, 440–441

Hypoventilation, controlled, with permissive hypercapnia, 585–586

- in liver cirrhosis, 50

Hypoxemia, arterial, in liver transplant recipients, 99–100

- mechanical ventilation and, 445–446
- mechanism of, 36–37
- transient, noninvasive ventilation and, 544–545

Hypoxic respiratory failure, noninvasive ventilation for, 525–526

Hypoxic pulmonary vasoconstriction (HPV), in cirrhosis, 138–140

Ibuprofen, for sepsis, 291–292

Imipenem, for sepsis, 179

Immune system, HIV infection effects on, 633–645. See also *Human immunodeficiency virus (HIV) infection, pulmonary complications*.

- respiratory tract-related, components of, 633–634
- nitric oxide and, 342

Immunosuppression, advanced, defined, 621

Immunotherapy, for sepsis, 307–317

Impedance, components of, 395

Independent lung ventilation, 591–601

- clinical considerations, 596–599

Infection(s), defined, 175

- extrapulmonary, *Pneumocystis carinii pneumonia* and**, 678–679
- gram-negative, pathogenesis, 307–309
- Infectious diseases, prevalence, trends in**, 623
- Inflammation, in sepsis, mediators and modulators of**, 201–205

Inflammatory cascade, interleukin-1 β 's effects on, in lipopolysaccharide-induced sepsis syndrome, 188

- tumor necrosis factor- α 's effects on, in lipopolysaccharide-induced sepsis syndrome, 186–187

Inflammatory cell activation, in sepsis, markers of, 205–209

Inflammatory mediators, in sepsis-induced MODS, hepatic production and export of, 88–90

- metabolic inactivation of, 90–91

Inflammatory reaction, nitric oxide during, 336–337

Inflammatory response, modulation of, hepatic acute-phase protein synthesis in, 91–93

Influenza, in HIV-infection, 749

Inotropy, defined, 238

Inspiratory pressure, in mechanical ventilation, 432

Inspiratory time, lengthening of, strategies for, 413–415

Integrin(s), β_2 , in sepsis-induced lung injury, 221

- in lipopolysaccharide-induced sepsis syndrome, 190–191

Intensive care, for HIV patients, 627–629

Interbronchial aspiration, 597

Intercellular adhesion molecule-1, in sepsis-induced lung injury, 221

Interferon-gamma, in lipopolysaccharide-induced sepsis syndrome, 189–190

Interleukin-1, in systemic inflammatory response syndrome, 155–156

Interleukin-6, in systemic inflammatory response syndrome, 156

Interleukin-1, as inflammatory mediator in sepsis, 204
 Interleukin-1 β , in lipopolysaccharide-induced sepsis syndrome, 187-188
 Interleukin-1 receptor antagonists, for sepsis, 312-313
 in lipopolysaccharide-induced sepsis syndrome, 188
 Interleukin-6, for sepsis, 313
 in lipopolysaccharide-induced sepsis syndrome, 188-189
 Interleukin-8, as inflammatory mediator in sepsis, 204
 for sepsis, 313
 in lipopolysaccharide-induced sepsis syndrome, 189
 Interleukin-10, as inflammatory mediator in sepsis, 204
 in lipopolysaccharide-induced sepsis syndrome, 189
 Intermittent mandatory ventilation (IMV), in weaning from mechanical ventilation, 482-483
 Intermittent positive-pressure ventilation (IPPV), for COPD patients with acute respiratory failure, 517-518
 Interstitial lung disease (ILD), AIDS-related, 634
 HIV infection in illicit drug users and, 801
 Intrapulmonary vascular dilatation, mechanism of, in hepatopulmonary syndrome, 37-38
 Intrinsic PEEP. See *Auto-positive end-expiratory pressure (PEEP)*.
 Intubation, 355-378
 endotracheal, equipment for, 362-366
 ethical issues related to, 372-373
 for prolonged airway management, 370-371
 medicolegal issues related to, 372
 retrograde endotracheal, 358, 359
 tracheal, techniques of, 355-361. See also *Tracheal intubation, techniques of*.
 translaryngeal. See *Translaryngeal intubation*.
 Isoniazid, for tuberculosis in HIV-infected patients, 700
 Isoproterenol, for sepsis, 282-283
 Isosporiasis, prevalence, trends in, 623

Jet ventilation, high-frequency, in newborns, 610-611

Kaposi's sarcoma, 755-758
 described, 755-756
 diagnosis, 756-757
 epidemiology, 756
 HIV infection in illicit drug users and, 804
 in HIV-infected children, 792
 in HIV-infected patients, fiberoptic bronchoscopy for, 777-778
 new developments in, 657
 pathogenesis, 756
 prevalence, trends in, 623
 prognosis, 757
 pulmonary, 756
 radiography of, 756
 treatment, 757-758
 Ketoconazole, for ARDS, 227
 Kupffer cell uptake, determinants of, during MOFs, 84-86
 Kupffer cell-hepatocyte interactions, 90-91

Laryngeal mask airway (LMA), for endotracheal intubation, 365
 Laryngoscope blades, for endotracheal intubation, 362, 363
 Larynx, injuries of, translaryngeal intubation and, 368-369

Left ventricular failure, as cause of difficulty in weaning from mechanical ventilation, 481-482
 Left ventricular function, in sepsis, 238-240, 242-243
Legionella sp., in HIV-1 infection, 715
 Leukotriene(s), in systemic inflammatory response syndrome, 157
 Leukotriene B₄ in lipopolysaccharide-induced sepsis syndrome, 190
 Leukoencephalopathy, prevalence, trends in, 623
 Lipid(s), metabolism of, in sepsis, 253-254
 Lipid A, in sepsis, 176
 Lipopolysaccharide(s), and induction of pulmonary intravascular macrophages in liver cirrhosis, 145
 entry into circulation, in sepsis-induced lung injury, 218
 sepsis syndrome due to, 183-184
 Lipopolysaccharide-CD14 interaction, sepsis syndrome due to, 184
 Liquid lung ventilation, 419
 Liver, dysfunction of, pulmonary pathophysiology associated with, 67-82
 nitric oxide and, 341-342
 Liver cirrhosis, 49-66. See also *Cirrhosis, liver*.
 Liver disease, chronic, lung vasculature changes in, 1-15
 pulmonary hypertension in, 17-33
 shunts in, 1-8
 cytokine biology in, 89
 experimental, intravascular phagocytosis in, 141-145
 in hepatopulmonary syndrome, 39
 pulmonary function testing in, 78-79
 pulmonary hypertension in, 8-12
 pulmonary intravascular phagocytosis in, 137-150.
 See also *Pulmonary intravascular phagocytosis*.
 Liver transplantation, early post-transplant considerations, 103-109
 for α_1 -antitrypsin deficiency, 73
 for hepatopulmonary syndrome, 115-123. See also *Hepatopulmonary syndrome, liver transplantation for*
 for pulmonary hypertension in chronic liver disease, 27-29
 gas exchange effects on, 61-62
 hypoxemia and, 99-100
 infectious complications, 106-109
 intraoperative considerations, 102-103
 late post-transplant considerations, 109-110
 lung-liver disorders and, 101
 malignancy and, 102
 noninfectious complications, 103-106
 pleural effusions and, 101-102
 pretransplant considerations, 99-102
 pulmonary complications, 99-114
 pulmonary edema and, 100-101
 pulmonary function abnormalities and, 102
 pulmonary hypertension and, 101
 Liver-lung disorders, in liver transplant recipients, 101
 L-selectin, in sepsis-induced lung injury, 220
 Lung(s), adenovirus infection of, 750
 compliance of, during mechanical ventilation, measurement of, 462-464
 damage to, ventilator-induced, 556-560
 Epstein-Barr virus of, in HIV-infection, 749
 HIV in, immunologic-related, 633-645
 mechanics of, during mechanical ventilation, measurement of, 462-470
 neutrophilic alveolitis effects on, 640-641
 resistance of, during mechanical ventilation, measurement of, 464
 Lung abscess, in illicit drug users, 801
 Lung cancer, in HIV-infected patients, 759-760

Lung injury, acute, current concepts of, 213–235
 sepsis-induced, molecular pathogenesis, 217–226

Lung injury score, components and individual values of, 214

"Lung protective" strategies, using conventional ventilator capabilities, 411–413

Lung separation, anatomic reasons for, 596–597
 physiologic reasons for, 597–599
 techniques of, 591–596

Lung transplantation, cystic fibrosis and, acute respiratory failure associated with, noninvasive ventilation for, 525
 for α_1 -antitrypsin deficiency, 72–73
 lung separation due to, 597–598

Lymphocyte(s), in lungs of HIV-infected patients, 634–638

T, cytotoxic, in HIV infection, 637
 HIV infection of, 641–642
 lung epithelial damage due to, 637–638

Lymphocytic alveolitis, HIV-related, 765–766
 pathogenesis, 635–636

Lymphocytic interstitial pneumonitis, HIV infection in illicit drug users and, 804
 in HIV infection, 763–766
 in HIV-infected children, 791–792

Lymphoma, non-Hodgkin's, 758–759. See also *Non-Hodgkin's lymphoma*.
 prevalence, trends in, 623

MAC disease, disseminated, 702–705
 clinical presentation, 703–704
 diagnosis, 704
 epidemiology, 702–705
 management, 704
 pathogenesis, 703
 prevention, 704–705

Macrophage(s), alveolar, in lungs of HIV-infected patients, 638–641
 pulmonary intravascular, 125–135. See also *Pulmonary intravascular macrophages*.

Macrophage alveolitis, AIDS-related, mechanisms in, 638

Malignancy, HIV-related, pulmonary complications, 755–761
 in liver transplant recipients, 102

Markers, defined, 199

of sepsis, 199–212. See also *Sepsis, markers of*
 antioxidants, 205
 complement, 203
 cytokines, 203–204
 endothelial cells, 207–209
 endotoxin, 201–203
 epithelial cells, 208–209
 functions of, 199–200
 inflammation mediators and modulators, 201–205
 inflammatory cell activation, 205–209
 interpretation of studies of, problems related to, 200
 monocytes, 206–207
 neutrophils, 205–206
 oxidants, 205
 phospholipids, 204–205

Mask ventilation, clinical application of, for COPD patients with acute respiratory failure, 518–522
 for COPD patients with acute respiratory failure, 516–518

Massive hemoptysis, 596

Maximum inspiratory airway pressure, during mechanical ventilation, measurement of, 462

Measles pneumonia, in HIV-infection, 749–750

Mechanical ventilation, acute respiratory distress due to, 441–442
 adjuncts to, 491–511
 for carbon dioxide removal, 492–498
 for improving oxygenation, 498–506
 future trends in, 506
 airway pressure release ventilation, 416–417
 airway resistance during, measurement of, 464
 auto-PEEP in, measurement of, 464–465
 barotrauma during, 445
 complications of, 439–451
 acute respiratory distress, 441–442
 blood from endotracheal tube, 446–447
 during initiation of positive-pressure ventilation, 439–440
 hypotension, 440–441
 hypoxemia, 445–446
 repeated high-pressure alarm, 442–445
 ventilator-associated pneumonia, 447–450
 conventional approach to, 555–556
 dynamic hyperinflation in, 429–430
 enhancements in pressure-limited breath, 415–416
 flow delivery in, 431–432
 gas exchange during, 453–460
 goals of, 423
 high-frequency ventilation, 417–419
 high-pressure alarm due to, 442–445
 hypotension due to, 440–441
 in ARDS, 229
 modes of, 570–571
 in COPD, 577–590. See also *Chronic obstructive pulmonary disease (COPD), mechanical ventilation in*
 liquid lung ventilation, 419
 long inspiratory time strategies, 413–415
 lung mechanics during, measurement of, 462–470
 lung protective strategies using conventional ventilator capabilities, 411–413
 monitoring during, 453–473
 ABGs in, 453–454
 airway occlusion pressure, 460
 airway pressure profile, 465
 capnography, 457–460
 flow–volume curves, 465–466
 breathing pattern, 460–462
 of maximal inspiratory airway pressure, 462
 of respiratory neuromuscular function, 460–462
 pressure–time product, 467–470
 pulse oximetry, 454–457
 work of breathing, 467
 new modes of, 411–421
 neonatal. See *Newborns, mechanical ventilation of*
 noninvasive, 486
 of newborns, 603–613. See also *Newborns, mechanical ventilation of*
 oxygenation during, 445
 patient agitation during, causes, 425
 patient-related factors in, 423–430
 respiratory center output, 423–426
 respiratory system mechanics, 426–430
 pneumothorax due to, 444
 posttrigger phase of, 430
 pressure-controlled, 400–403
 proportional-assist ventilation, 419
 trigger phase of, 430
 ventilator-related factors in, 430
 apparatus resistance, 432
 flow delivery, 431–432
 inspiratory pressure, 432
 tidal volume, 432

ventilator triggering, 430–431
 volume-cycled, 395–400. See also *Volume-cycled ventilation*.
 weaning from, 475–489
 computer-assisted, 486
 conditions required for, 475–478
 difficult-to-wear patients, 484–486
 incidence, 484
 management, 484–486
 difficulty in, postextubation respiratory failure and, 533–535
 extubation criteria in, 478
 future developments in, 486
 intermittent mandatory ventilation in, 482–483
 methods of, 482–484
 outcome of, predictive indexes of, 477
 pressure-support ventilation in, 483
 problems related to, 478–482
 pulmonary gas exchange in, 476
 respiratory system capacity in, 476–478
 T-piece trials in, 482
 Mediastinal infections, in illicit drug users, 801
 Medicolegal issues, in intubation, 372
 Metabolic disorders, inherited, α_1 -antitrypsin deficiency, 151–152
 hepatopulmonary syndrome, 152–155
 Metabolism, alterations in, sepsis-induced, altered calcium homeostasis in, 255–257
 Methylprednisolone, for sepsis, 180
 Microbe(s), nitric oxide and, 337–339
 Midazolam, for translaryngeal intubation, 366
 MIGET. See *Multiple inert gases elimination technique*.
 Minitracheostomy, 360, 362
 MOFS. See *Multiple organ failure syndrome*.
 Monocyte(s), in inflammatory cell activation in sepsis, 206–207
 Mucormycosis, 741
 Multiple inert gases elimination technique (MIGET), in liver cirrhosis, 51–55
 Multiple organ failure syndrome (MOFS), cardiopulmonary homeostasis during, gut-liver axis of, 84–86
 sepsis-induced, hepatic production and export of inflammatory mediators in, 88–90
 lung-liver interactions in, 83–98
 described, 83
 Q_l, 86–88
 Multiple-organ dysfunction syndrome (MODS), ARDS in, 216
 defined, 175
 described, 249
 Multi-system organ failure (MSOF), in sepsis, 272
 Muscular dysfunction, as cause of difficulty in weaning from mechanical ventilation, 480–481
Mycobacteria genavense, nontuberculous mycobacterial infection in HIV-infected patients due to, 701, 705
Mycobacteria haemophilum, nontuberculous mycobacterial infection in HIV-infected patients due to, 701, 706
Mycobacteria kansasii, nontuberculous mycobacterial infection in HIV-infected patients due to, 701, 705
Mycobacteria xenopi, nontuberculous mycobacterial infection in HIV-infected patients due to, 701, 706
 Mycobacterial diseases, in HIV-infected patients, 701
 nontuberculous, 702
 Mycobacteriosis, nontuberculous, prevalence, trends in, 623
Mycobacterium avium complex (MAC), new developments in, 656–657
Mycobacterium avium-intracellulare infection, in HIV-infected children, 790
 Myocardial dysfunction, mechanism of, 243–245
 Myocardium, nitric oxide and, 341

 Naloxone, for sepsis, 299–300
 Narcotics, for translaryngeal intubation, 366
 Neonates. See *Newborns*.
 Neurologic disorders, as cause of difficulty in weaning from mechanical ventilation, 478
 Neuromuscular blockade, for translaryngeal intubation, 367
 Neutrophil(s), functions of, granulocyte colony-stimulating factor and, 322–323
 in inflammatory cell activation in sepsis, 205–206
 organ injury due to, 327–328
 Neutrophilic alveolitis, in HIV-infected patients, 640
 lung damage due to, 640–641
 Newborns, mechanical ventilation of, 603–613
 carbon dioxide removal in, 608–609
 conventional, application of, 607–609
 high-frequency techniques, application of, 609–611
 carbon dioxide removal during, 611
 jet ventilation, 610–611
 oscillation, 611
 oxygenation during, 611
 positive-pressure ventilation, 610
 history of, 604–607
 monitoring of, 609
 oxygenation in, 608
 ventilators in, 607
 Nitric oxide, and endothelial activation, 341
 and gut, 342
 and immunity, 342
 and liver, 341–342
 and microbes, 337–339
 and myocardium, 341
 described, 333
 during inflammatory reaction, 336–337
 during septic shock, 339–342
 for improving oxygenation, in mechanical ventilation, 498–499
 in ARDS, 568–570
 in hepatopulmonary syndrome, 154–155
 in lipopolysaccharide-induced sepsis syndrome, 190
 in sepsis, 333–350
 in vasoplegia, 340–341
 inducible, 342–343
 regulation of, 336
 inhaled, for ARDS, 228
 manipulation of, in sepsis, 343–345
 physiologic targets of, 335–336
 Nitric oxide synthases, 334–335
Nocardia sp., in HIV-1 infection, 715
 Non-Hodgkin's lymphoma, described, 758
 diagnosis, 759
 epidemiology, 758
 HIV infection in illicit drug users and, 804
 in HIV-infected patients, 758–759
 pathogenesis, 758–759
 pathology of, 758–759
 prognosis, 759
 pulmonary involvement in, 759
 treatment, 759
 Noninvasive ventilation, advantages of, 542–544
 comfort of patient, 537
 cost-effectiveness of, 545
 disadvantages of, 544–545
 education and implementation of, 545
 in acute respiratory failure, 513–553

Noninvasive ventilation (*Continued*)

- in asthmatics, 522-524
- in AIDS patients, 530-531
- in ARDS, 528-529
- in atelectasis, 532
- in community-acquired pneumonia, 531-532
- in COPD, 516-522
- in cystic fibrosis, 525
- in hypercapnic respiratory failure, 516
- in hypoxic respiratory failure, 525-526
- in pediatric hypoxic acute respiratory failure, 532-533
- in postoperative respiratory failure, 529-530
- in trauma patients, 530
- interface in, 535-537
- masks for, 536
- mode of, 537
- monitoring during, 541-542
- patient selection for, 535
- portable ventilators for, 540
- predictors of success, 542
- weaning from, 542

Nonspecific interstitial pneumonitis, in HIV infection, 764-765

NUCA 3001, for HIV infection, 651

NUCA 3002, for HIV infection, 653

NUCB 3002, for HIV infection, 653

Octreotide, gas exchange effects on, 60

Oscillation, high-frequency, in newborns, 611

Oxidant(s) as inflammatory mediator in sepsis, 205

Oxygen, utilization of, in sepsis, 250-251

Oxygen consumption, during sepsis, 263-278

- management, 274-275
- oxygen delivery and, relationship between, 263-271

Oxygen delivery, during sepsis, 263-278

- management, 274-275
- oxygen consumption and, relationship between, 263-271

Oxygenation, during high-frequency ventilation in newborns, 611

- in mechanical ventilation, adjuncts for improving, 498-506
- in neonatal mechanical ventilation, 608

Paracentesis(es), large-volume, pulmonary function changes following, 77-78

Paracoccidioidomycosis, 737-738

- clinical features, 738
- diagnosis, 738
- epidemiology, 738
- microbiology of, 737-738
- prevention, 738
- treatment, 738

Parasitic infections, in HIV-infection, 750-751

Partial liquid ventilation, in ARDS, 567-568

Patient-ventilator interactions, 423-438. See also *Mechanical ventilation, patient-related factors in; Mechanical ventilation, ventilator-related factors in*

- improvements in, strategies for, 432-435

Pentamidine, for *Pneumocystis carinii* pneumonia, 681-684

- for sepsis, 179

Pentoxifylline, for sepsis, 294

Percutaneous dilatational tracheostomy, 359-360, 361

Perflubron, for ARDS, 227-228

Perfluorocarbon-associated gas exchange, for improving oxygenation, in mechanical ventilation, 502-504

Permissive hypercapnia, in ARDS, 565

Phagocytosis, pulmonary, intravascular, in humans, 146-147

- phagocytosis. See *Pulmonary intravascular phagocytosis*.

Phenylephrine, for sepsis, 282

- gas exchange effects on, 60

Phospholipid(s), as inflammatory mediator in sepsis, 204-205

Phycon Univent tube, for endotracheal intubation, 362, 363

Piperacillin, for sepsis, 179

Plasmapheresis, gas exchange effects on, 60

Platelet-activating factor (PAF), in hepatopulmonary syndrome, 154

- in lipopolysaccharide-induced sepsis syndrome, 190
- in systemic inflammatory response syndrome, 157

Platelet-activating factor antagonists, for sepsis, 292-294

Pleural disease, in pulmonary disease evaluation in HIV-infected patients, 778-780

Pleural effusion(s), 76-77

- following liver transplantation, 104
- in liver transplant recipients, 101-102

Pleural infections, in illicit drug users, 801

Pneumocystis carinii pneumonia, 665-695

- acute respiratory failure in, prognostic markers of, 676-678
- AIDS and, 621
- biology of, 665-669
- cell structure of, 666
- chemoprophylaxis, 684-686
- clinical manifestations, 669-680
- clinical presentation, 670-672
- disease severity, prognostic markers of, 676-678
- epidemiology, 668-669
- extrapulmonary infection in, 678-679
- following liver transplantation, 108-109
- historical perspective, 665
- HIV-related deaths due to, 621
- host pulmonary defense mechanisms in, 667-668
- host-pathogen interactions in, 666-667
- in HIV-infected children, 788-789
- in HIV-infected patients, blood tests for, 772
 - sputum examination for, 773
- in HIV-seropositive patients, incidence, 669-670
 - risk of, 670
- intensive care of patients with, 627-628
- life cycle of, 666
- new developments in, 655-656
- pathologic manifestations, 679-680
- pulmonary function tests in, 672-673
- pulmonary processes with, 680
- radiographic manifestations, 673-676
- taxonomy of, 665-666
- treatment, 680-686
 - clindamycin-primaquine, 682-683
 - corticosteroids, 683-684
 - empiric versus diagnostic-directed, 680-681
 - TMP-SMZ, 681-684
 - trimethoprim-dapsone for, 683
 - trimetrexate, 683

Pneumocystosis, prevalence, trends in, 623

Pneumonia, atypical, in HIV infection, 751

- bacterial, following liver transplantation, 106-107
 - in HIV-type 1 infection, 713-723. See also *Human immunodeficiency virus (HIV) infection-type 1, bacterial pneumonia associated with*
- prevalence, trends in, 623

community-acquired, acute respiratory failure in, non-invasive ventilation for, 531–532
 fungal, following liver transplantation, 109
 in illicit drug users, 801
 measles, in HIV infection, 749–750
 nosocomial, in HIV-type 1 infection, 715–716
Pneumocystis carinii, 665–695. See also *Pneumocystis carinii* pneumonia.
 following liver transplantation, 108–109
 ventilator-associated, 447–450
 viral, in illicit drug users, 801

Pneumonitis, CMV, in HIV infection, 746–748
 HSV, in HIV infection, 748–749
 lymphocytic interstitial, HIV infection in illicit drug users and, 804
 in HIV infection, 763–766
 in HIV-infected children, 791–792
 nonspecific interstitial, in HIV infection, 764–765
 VZV, in HIV infection, 749

Pneumothorax, in ventilated patients, 444

Portal hypertension, noncirrhotic, 76

Positive end-expiratory pressure (PEEP), application of, determination of, 391–393
 external, in COPD, 580–581
 in ARDS, 560–561
 in ventilatory failure, 379

Positive-pressure ventilation, high-frequency, in newborns, 610
 initiation of, problems during, 439–440
 noninvasive, clinical application of, 520–522

Positive-pressure ventilatory support, lung-liver interactions during, 86–88

Preload, defined, 238

Pressure-controlled ventilation, 400–403
 auto-PEEP in, 401, 403
 clinical studies, 406–408
 indications, 408
 inspiratory resistance in, 401
 inspiratory time in, 401
 respiratory system compliance in, 401
 tidal volume determinants in, 401–403
 to volume-cycled ventilation, mode interconversion, 403–406
 versus volume-cycled ventilation, 395

Pressure-limited breath, enhancements in, 415–416

Pressure-support ventilation, in weaning from mechanical ventilation, 483

Pressure-time product, during mechanical ventilation, measurement of, 467–470

Pressure-volume curves, during mechanical ventilation, measurement of, 461–462

Primary biliary cirrhosis (PBC), 74–75

Prone positioning, for improving oxygenation, in mechanical ventilation, 504–506
 in ARDS, 566–567

Propofol, for tracheal intubation, 366–367

Proportional-assist ventilation, 419

Prostacyclin, inhaled, in ARDS, 568–570

Prostaglandin metabolites, in lipopolysaccharide-induced sepsis syndrome, 190

Protein(s), metabolism of, in sepsis, 253

Protein synthesis, hepatic acute-phase, inflammatory response modulation by, 91–93

Proteinosis, pulmonary alveolar, 596–597

P-selectin, in sepsis-induced lung injury, 220

Pulmonary alveolar proteinosis, 596–597

Pulmonary angiography, in hepatopulmonary syndrome, 42–44

Pulmonary artery hypertension, 17

Pulmonary calcifications, following liver transplantation, 105–106

Pulmonary cells, pathogenesis, retroviral infection of, 641

Pulmonary circulation, alterations in, cirrhosis-associated, pulmonary intravascular macrophages in, 144–145

Pulmonary complications, in lungs of HIV-infected patients, 640–641

Pulmonary edema, cardiogenic, acute respiratory distress in, noninvasive ventilation for, 526–528
 HIV infection in illicit drug users and, 802–803
 in liver transplant recipients, 100–101

Pulmonary embolism, septic, in illicit drug users, 800–801

Pulmonary function, abnormalities associated with, in liver transplant recipients, 102

Pulmonary function tests, in liver disease, 78–79
 in *Pneumocystis carinii* pneumonia, 672–673
 in pulmonary disease evaluation in HIV-infected patients, 771

Pulmonary gas exchange, in weaning from mechanical ventilation, 476

Pulmonary hyperinflation, in COPD, 581–585

Pulmonary hypertension, defined, 17
 histology, 18–19
 subclassification of lesions, 19

history of, 17–18
 in chronic liver disease, 17–33
 causes, 20–21
 demographics, 19–20
 diagnosis, 22–24
 endothelial cell, 21–22
 features, 25
 liver transplantation for, 27–29
 natural history, 25–26
 pharmacotherapy, 24–25
 prognostic factors, 26–27
 survival following, 25
 in liver disease, 8–12
 in liver transplant recipients, 101
 incidence, 19–20
 pulmonary intravascular phagocytosis and, 147

Pulmonary infections, in illicit drug users, 799–801

Pulmonary intravascular macrophages, as source of inflammatory mediators, 131
 described, 125
 in acute lung injury, 125–135
 experimental approaches to, 131–133
 induction of, 132–133
 isolation for in vitro study, 131–132
 phagocytic function, 127
 role of, 128–131
 in cirrhosis-associated pulmonary circulatory alterations, 144–145
 in liver cirrhosis, induction of, mechanisms for, 145–146
 in pulmonary intravascular phagocytosis in chronic liver disease, 144
 in sheep, inactivation of depletion of, 133
 liver-lung interactions in species with, 130–131
 species distribution of, 128

Pulmonary intravascular phagocytosis, and ARDS, 148–149
 clinical consequences, 147–149
 described, 137
 in humans, 146–147
 in liver disease, 137–150
 pulmonary intravascular macrophages in, 144

Pulmonary lymphoid hyperplasia, in HIV-infected children, 791–792

Pulmonary system, HIV infection effects on. See Human immunodeficiency virus (HIV) infection, pulmonary complications.

Pulmonary vascular disease, HIV infection in illicit drug users and, 802
 Pulse oximetry, accuracy of, 454–455
 clinical applications of, 456–457
 in pulmonary disease evaluation in HIV-infected patients, 772
 limitations of, 455–456
 principles of, 454

Q_{v} , in sepsis-induced MOFS, 86–88

Radiology, interventional, gas exchange effects on, 60–61
 Radionuclide scans, in pulmonary disease evaluation in HIV-infected patients, 769–771
 Respiration, in HIV infection, 625–626
 Respiratory distress, acute, mechanical ventilation and, 441–442
 Respiratory failure, hypoxicemic, noninvasive ventilation for, 525–526
 postoperative, noninvasive ventilation for, 529–530
 Respiratory neuromuscular function, measurement of, during mechanical ventilation, 460–462
 Respiratory pump failure, as cause of difficulty in weaning from mechanical ventilation, 480–481
 Respiratory syncytial virus (RSV) infection, in HIV infection, 749
 Respiratory system capacity, in weaning from mechanical ventilation, 476–478
 Respiratory tract, infections of, in HIV-type 1 infection, 720
 Respiratory workload, increase in, as cause of difficulty in weaning from mechanical ventilation, 478–480
 Rest, gas exchange at, 50–55
 Retrograde endotracheal intubation, 358, 359
 Rhinovirus infection, in HIV infection, 750
Rhodococcus sp., in HIV-type 1 infection, 715
 Rib cage-abdominal motion, during mechanical ventilation, measurement of, 461
 Rifampin, for tuberculosis in HIV-infected patients, 700
 Right ventricular function, in sepsis, 240–243
 Rubeola, in HIV infection, 749–750

Sedative(s), for translaryngeal intubation, 366–367
 Selectin(s), counter-receptors for, in sepsis-induced lung injury, 220–221
 in sepsis-induced lung injury, 219–220
 Sepsis. See also *Sepsis syndrome*.
 N-acetylcysteine for, 297–299
 anti-cytokines for, 310–313
 anti-endotoxins for, 309–310
 antioxidants for, 295–297
 ARDS in, 213–235
 frequency of, 215–216
 treatment, 228
 aspirin for, 290–291
 blood cultures in, 177–178
 bradykinin antagonists for, 200
 by-products of, hepatic control of, 84–88
 clinical studies of, problems related to, 200
 colony-stimulating factors in, 320
 current concepts of, 213–235
 cyclooxygenase inhibitors for, 289–292
 defined, 175

described, 213
 diagnosis, 177–178
 early detection of, 199–212
 energy substrate utilization alterations in, 249–255
 fluid management in, 279–281
 fungal, hepatic cytokine production in, 89–90
 glucose metabolism in, 251–253
 granulocyte colony-stimulating factor and modulation of inflammatory cells in, 319–332
 granulocyte colony-stimulating factors in, 320–322
 hemodynamic support during, 279–287
 human models of, 245–246
 ibuprofen for, 291–292
 immunotherapy for, 307–317
 incidence, 176–177, 213
 inflammatory cell activation in, markers of, 205–206
 interleukin-1 receptor antagonists for, 312–313
 interleukin-6 for, 313
 interleukin-8 for, 313
 left ventricular function in, 238–240, 242–243
 lipid metabolism in, 253–254
 lung injury due to, molecular pathogenesis, 217–226
 markers of, 199–212. See also *Markers, of sepsis*.
 defined, 199
 functions of, 199–200
 interpretation of studies of, problems related to, 200
 metabolic alterations in, altered calcium homeostasis in, 255–257
 metabolic consequences of, 249–261
 future directions in, 257–258
 MOFS due to, 83–98. See also *Multiple organ failure syndrome (MOFS), sepsis-induced*.
 multi-system organ failure in, 272
 naloxone for, 299–300
 nitric oxide in, 333–350
 oxygen consumption during, 263–278
 oxygen delivery during, 263–278
 oxygen utilization in, 250–251
 pathogenesis, 183–197
 pathophysiology, 176
 pentoxifylline for, 294
 platelet-activating factor antagonists for, 292–294
 protein metabolism in, 253
 right ventricular function in, 240–243
 sputum culture in, 178
 treatment, 178–180
 pharmacologic, 289–305
 tumor necrosis factor for, 311–312
 urine specimen in, 178
 vasopressors for, 282–286
 Sepsis syndrome. See also *Sepsis*.
 defined, 183
 initiators of, 183–184
 lipopolysaccharide-induced, 183–184
 adhesion molecules in, 190–191
 arachidonic acid metabolites in, 190
 complement in, 190
 cytokine induction in, 185–190
 Fc receptors in, 191
 immunologic mediators of, 184–191
 integrins in, 190–191
 interferon-gamma in, 189–190
 interleukin-1B in, 187–188
 interleukin-1 receptor antagonist in, 188
 interleukin-6 in, 188–189
 interleukin-8 in, 189
 interleukin-10 in, 189
 leukotriene B₄ in, 190
 nitric oxide in, 190

platelet-activating factor in, 190
prostaglandin metabolites in, 190
tumor necrosis factor- α in, 185–186
tissue hypoxia in, supernormal oxygen delivery and, 271–274
treatment, antibiotics, 178–180
 general approach to, 175–181
Septic shock, cardiac dysfunction during, 237–248
 prognosis, 243
 treatment, implications for, 246–247
death due to, causes, 237
defined, 175
nitric oxide during, 339–342
Septicemia, prevalence, trends in, 623
Sheep, pulmonary intravascular macrophages in, inactivation of depletion of, 133
Shock, classification of, 237, 238
 defined, 237
 septic. See *Septic shock*.
Shunt(s), in chronic liver disease, 1–8
 pathways for, 1–8
Shunting, arteriovenous, in liver cirrhosis, 50–51
Sinusitis, translaryngeal intubation and, 368
Sleep apnea, acute respiratory failure in, noninvasive ventilation for, 524–525
Somatostatin analogue, gas exchange effects on, 60
Sporotrichosis, 739
Sputum culture, in sepsis, 178
Streptococcus pneumoniae, in HIV-type 1 infection, 713, 714–715
Stress, hepatic oxidative nonbacteremic versus bacteremic, cytokine kinetics during, 90
Strongyloidiasis, pulmonary, in HIV infection, 751
Stylet(s), illuminating, for endotracheal intubation, 365, 366
Substance P, in hepatopulmonary syndrome, 154
Surfactant, in ARDS, 566
Surfactant replacement, for ARDS, 227
Surfactant replacement therapy, for improving oxygenation, in mechanical ventilation, 499–502
Systemic inflammatory response (SIRS), defined, 175
Systemic inflammatory response syndrome (SIRS), mediators in, 155–157

T lymphocytes, cytotoxic, in HIV infection, 637
 HIV infection of, 641–642
 lung epithelial damage due to, 637–638
Technetium- 99m macroaggregated albumin body scan, in hepatopulmonary syndrome, 41
The germinal matrix, 603
Thoracic wall abnormality, as cause of difficulty in weaning from mechanical ventilation, 480
Thoracoscopy, in pulmonary disease evaluation in HIV-infected patients, 778
Thoracotomy, in pulmonary disease evaluation in HIV-infected patients, 778
Tidal compliance, in ARDS, 563
Tidal recruitment, in ARDS, 563
Tidal volume, in mechanical ventilation, 432
 minimization of, 413
 pressure limitation for, implications of, 563–564
TMP-SMZ. See *Trimethoprim-sulfamethoxazole*.
Tobramycin, for sepsis, 179
Toxoplasmosis, prevalence, trends in, 623
 pulmonary, in HIV-infection, 750
T-piece trials, in weaning from mechanical ventilation, 482
Tracheal extubation, 369–370

Tracheal gas insufflation, in ARDS, 568
 in mechanical ventilation, 496–498
Tracheal intubation, techniques of, 355–361
 cricothyroidectomy, 360
 endotracheal tube exchange over a catheter, 359, 361
 minitracheostomy, 360, 362
 percutaneous dilatational tracheostomy, 359–360, 361
 preparation for, 355–357
 retrograde endotracheal intubation, 358, 359
 with flexible fiberoptic bronchoscope, 358
 with gum elastic bougie, 359, 360
Tracheostomy, percutaneous dilatational, 359–360, 361
Tracheotomy, for prolonged airway management, 371–372
Transient hypoxemia, noninvasive ventilation and, 544–545
Translaryngeal intubation, complications of, in critically ill patients, 367–369
 credentialing in, 373
 laryngeal injury due to, 368–369
 pharmacologic agents for, 366–367
 preparation for, 355–357
 sinusitis due to, 368
 training in, 373
 with flexible fiberoptic bronchoscope, 358
Transplantation, liver. See *Liver transplantation*.
lung, cystic fibrosis and, acute respiratory failure associated with, noninvasive ventilation for, 525
 for α -antitrypsin deficiency, 72–73
 lung separation due to, 597–598
Transthoracic needle aspiration (TTNA), in pulmonary disease evaluation in HIV-infected patients, 778
Trauma, acute respiratory failure in, noninvasive ventilation for, 530
Trimethoprim-dapsone, for *Pneumocystis carinii* pneumonia, 683
Trimethoprim/sulfamethoxazole (TMP/SMZ), adverse reactions to, 681–682
 for *Pneumocystis carinii* pneumonia, 681–684
 for sepsis, 179
Trimetrexate, for *Pneumocystis carinii* pneumonia, 683
Tuberculin skin testing, in HIV-infected patients, 699
Tuberculosis, in HIV-infected children, 789–790
 in HIV-infected patients, 697–702
 bacteriologic and histologic examinations in, 699–700
 blood tests for, 772
 causative agents, 700–702
 clinical features, 699
 fiberoptic bronchoscopy for, 776
 incidence, 697–698
 prevalence, 697–698
 prevention, 702
 radiographic features, 699
 sputum examination for, 773–775
 treatment, 700
 in illicit drug users, 800
 multidrug-resistant organisms and, 700–702
 pathogenesis, in HIV-infected patients, 698–699
 prevalence, trends in, 623
Tumor necrosis factor- α , in lipopolysaccharide-induced sepsis syndrome, 185–190
Tumor necrosis factor (TNF), as inflammatory mediator
 in sepsis, 203–204
 for sepsis, 311–312
 in systemic inflammatory response syndrome, 156–157

Unilateral lung disease, lung separation due to, 597
 Univent tube, in lung separation, 591-592
 Urine specimen, in sepsis, 178

Valacyclovir, for CMV, 660
 Vancomycin, for sepsis, 179
 Varicella zoster virus (VZV), following liver transplantation, 108
 Varizella zoster virus (VZV) pneumonitis, in HIV infection, 749
 Vasoactive intestinal peptide (VIP), in hepatopulmonary syndrome, 153
 Vasodilator(s), for ARDS, 227
 Vasoplegia, nitric oxide in, 340-341
 Vasopressor(s), for sepsis, 282-286
 Venousous intravena caval oxygenator, in mechanical ventilation, 494-496
 Ventilation, airway pressure release (APRV), 416-417
 equipment for, 362-366
 high-frequency, 417-419
 in ARDS, 563-566
 independent lung, 591-601
 intermittent mandatory, in weaning from mechanical ventilation, 482-483
 liquid lung, 419
 mask. See *Mask ventilation*.
 mechanical. See *Mechanical ventilation*.
 in ARDS, 229
 noninvasive, in acute respiratory failure, 513-553. See also *Noninvasive ventilation, in acute respiratory failure*.
 partial liquid, in ARDS, 567-568
 positive-pressure, initiation of, problems during, 439-440
 preset pressure. See *Pressure-controlled ventilation*.
 pressure-controlled. See *Pressure-controlled ventilation*.
 pressure-support, in weaning from mechanical ventilation, 483
 prone position, in ARDS, 229-230
 proportional-assist, 419
 volume-cycled. See *Volume-cycled ventilation*.
 Ventilation-perfusion (VA/Q) mismatching, in liver cirrhosis, 51
 Ventilator(s), lung damage due to, 556-560
 neonatal versus adult, 607
 portable, for noninvasive ventilation, 540
 Ventilator triggering, 430-431
 Ventilatory support, for ARDS, 555-575. See also *Acute respiratory distress syndrome (ARDS), ventilatory management of*.

weaning from, 475-489. See also *Mechanical ventilation, weaning from*.
 Ventricular compliance, defined, 238
 Viral infections, in HIV-infected children, 790-791
 pulmonary, in HIV infection, 745-754
 adenovirus infection, 750
 atypical pneumonia, 751
 Bordetella infections, 751
 herpesvirus infections, 746-749
 influenza, 749
 measles pneumonia, 749-750
 parasitic infections, 750-751
 primary infections, 745-746
 respiratory syncytial virus, 749
 rhinovirus infection, 750
 secondary infections, 746
 Viral pneumonia, in illicit drug users, 801
 Volume-cycled ventilation, 395-400
 auto-PEEP in, 396-398
 clinical studies, 406-408
 flow profile in, 399-400
 flow rate in, 398-399
 indications, 408
 inspiratory resistance in, 396
 mean airway pressure in, 398
 pressure determinants in, 396
 respiratory system compliance in, 396
 to pressure-controlled ventilation, mode interconversion, 403-406
 ventilator settings in, 398-399
 versus pressure-controlled ventilation, 395
 Volutrauma, 491
 versus barotrauma, in ARDS, 560
 VZV. See *Varizella zoster virus*.

Weaning, from ventilatory support, 475-489. See also *Mechanical ventilation, weaning from*.
 Workload, respiratory, increase in, as cause of difficulty in weaning from mechanical ventilation, 478-480

Zidovudine (AZT), described, 647
 for HIV infection, 647, 649-650
 Zygomycosis, 741

